With a precise understanding of policies and markets in China's pharmaceutical and healthcare industry and leveraging long-term close cooperation with drug supervision authorities, health administration departments, and pharmaceutical industry associations, JT&N has long provided comprehensive legal services for pharmaceutical and medical enterprises, hospitals, and other healthcare providers, represented different types of Chinese and foreign pharmaceutical and healthcare enterprises (including but not limited to well-known large pharmaceutical companies, medical device companies, emerging biotechnology companies, pharmaceutical research outsourcing organizations, health product companies, etc.) in legal services such as M&A, joint ventures, technology licensing and cooperative development, compliance and anti-corruption investigations, and daily business compliance reviews, and assisted investors in completing various projects involving the system reform, restructuring, investment, M&A, domestic and foreign financing, and listing of medical institutions and pharmaceutical enterprises.
SERVICE
Compliance Advice and Review
Transaction Structure Design and Agreement Arrangement
Expansion of Product Line and Market Area
Project Financing, M&A, and Restructuring
Intellectual Property Protection
Licensing and Distribution Agreement
Dispute Resolution for Adverse Reaction Events in Clinical Trial and Treatment
DEALS
Assisted Jin Merchants Alliance and its actual controller in acquiring the control of the A-share listed company Tonghua Golden-Horse, followed by a series of capital operations including private placement, restructuring, and bond issuance, including the acquisition of the Harbin Shengtai's pharmaceutical project (one of the top ten classic pharmaceutical M&A cases in 2015), holding the largest imaging diagnostic service center IMed Group in Australia, and the Australian large medical imaging company ICON project, Chengdu Yongkang's pharmaceutical project, and six hospitals under LongMay Group (involving public hospital system reform), ultimately successfully selling the control of the A-share listed company and realizing exit, involving a transaction target amount of approximately 30 billion yuan
Provided ongoing legal advice services for a well-known American-funded pharmaceutical company, assisting in analyzing business compliance issues and deploying lawyers for long-term on-site service
Provided specialized anti-corruption compliance training for a globally top 3 renowned pharmaceutical company
Assisted QI-Biodesign Technology in completing seed round financing with an amount of over 100 million yuan, one of the largest seed round investments in gene editing companies announced in China
Provided long-term clinical trial agreement review services for emerging biotech companies such as Immune-Onc Therapeutics and Abbisko Therapeutics
Provided patent acquisition and other various technical cooperation agreement review services for Sparx Therapeutics
Provided unfair competition investigation services for a well-known medical device company in Shanghai regarding its former senior executives
Provided M&A services and data compliance services for a well-known pharmaceutical and medical industry fund in Shanghai
Provided Chinese legal due diligence services for a well-known American company regarding its global acquisition of a leading SaaS supplier in the pharmaceutical industry
Provided market entry and compliance operation services in China for a well-known U.S.-invested health product company
Provided legal services on cooperation review and joint venture with several global well-known pharmaceutical companies for Hong Kong Winhealth Pharma Group